Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

Technology appraisal guidance
Reference number: TA650
Published: 30 September 2020

Register as a stakeholder

Evidence

Supporting evidence

Evaluation report
Appraisal consultation committee papers (PDF 5.31 MB)

Published:

30 September 2020
Final appraisal determination committee papers (PDF 1.27 MB)

Published:

30 September 2020